Naperville, IL, United States of America

Gary E Schiltz

USPTO Granted Patents = 22 (Patent Applications = 16)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 36(Granted Patents)

Company Filing History:

21 out of 2,112

Northwestern University

Years Active: 2014-2025

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12414995 - Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer (2025-09-16),

2. 12311029 - Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein (2025-05-27),

3. 12252492 - Substituted fused pyrrolo-diazepinones and uses thereof (2025-03-18),

4. 12152007 - Substituted heterocycles as c-MYC targeting agents (2024-11-26),

5. 12042543 - Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 (2024-07-23),

6. 11981678 - Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) protein (2024-05-14),

7. 11919855 - Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding (2024-03-05),

8. 11890346 - Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein (2024-02-06),

9. 11839659 - Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein (2023-12-12),

10. 11453640 - Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy (2022-09-27),

11. 11420957 - Substituted heterocycles as c-MYC targeting agents (2022-08-23),

12. 11370770 - 3-arylindazoles as selective MEK4 inhibitors (2022-06-28),

13. 11225483 - Substituted fused pyrrolo-diazepinones and uses thereof (2022-01-18),

14. 11142504 - Substituted heterocycles as c-MYC targeting agents (2021-10-12),

15. 10851082 - Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) (2020-12-01),

Title: Celebrating Innovation: The Impact of Gary E. Schiltz

Introduction: Gary E. Schiltz, based in Naperville, IL, is a notable inventor with a remarkable portfolio of 20 patents. His innovative contributions primarily lie in the field of pharmaceuticals, particularly in the development of compounds aimed at treating diseases associated with cell proliferation, including cancer.

Latest Patents: Among his latest patents, Schiltz has developed substituted fused pyrrolo-diazepinones, which comprise pharmaceutical compositions and methods of treatment. These compounds are derived from fused 1,4-diazepine and pyrrolidinedione scaffolds, showcasing his ability to create impactful therapeutic options for serious health conditions. Another significant patent involves substituted heterocycles functioning as c-MYC targeting agents. This patent details various substituted heterocycle compounds, including pyrazoles, pyrimidines, and triazoles, which can inhibit c-MYC, presenting promising therapeutic approaches for treating cancer and cell proliferative disorders.

Career Highlights: Throughout his career, Gary E. Schiltz has contributed greatly to the field of pharmaceuticals through his innovative research and development efforts. His work has extended into significant institutions such as Northwestern University and Decode Genetics Ehf, where he has been involved in groundbreaking faculty research.

Collaborations: Schiltz has collaborated with distinguished colleagues, including Rama K. Mishra and Karl A. Scheidt. These partnerships have fostered a rich environment for pioneering research and the development of new therapeutic solutions.

Conclusion: Gary E. Schiltz's extensive patent portfolio and dedication to overcoming challenges in the pharmaceutical arena have solidified his position as an influential inventor. His work continues to inspire innovation and advances in medical science, ultimately contributing to better treatment options for patients battling serious health issues.

This text is generated by artificial intelligence and may not be accurate.